Canadas Cardiovascular therapeutics market size stood at around USD XX.X billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 3.8% during the forecast period.

Cardiovascular diseases are the leading cause of death in Canada. In 2019, around 189 out of 100,000 Canadians died from major cardiovascular diseases. In addition, Cardiovascular Diseases are associated with significant health consequences for the individual and result in high medical costs for society. As per the Heart & Strokes analysis of Canadian hospitalization data, between 2007-2017, there was a 68% increase in hospitalizations across all age groups for cardiovascular disease.



Market Driving Factors

The major factors driving the growth of the market in Canada are due to the increasing burden of cardiovascular diseases and increased adoption of minimally invasive procedures. The market is driven by a host of factors which includes rise in aging population, rise in per capita spending on healthcare and epidemic of general medical issues like obesity and diabetes. As per the Heart and Stroke Foundation 2019 report, each year more than 62,000 people get attack with stroke in Canada, and that number is expected to rise. More than 405,000 people in the country live with the effects of stroke. Thus, owing to the high prevalence of heart diseases in Canada which is expected to show a significant growth rate over the forecast period.

Major Cardiovascular Diseases

Canada cardiovascular therapeutics market can be segmented based on type of disease. These various cardiovascular diseases are Ischemic heart disease, Cerebrovascular disease (Stroke), Peripheral vascular disease, Heart failure, Rheumatic heart disease, Congenital heart disease. Among these, Ischemic heart disease is the most common type of cardiovascular disease in Canada, it refers to problems with the circulation of blood to the heart muscle.